2.50

0.79% -0.02

After Hours: 2.43 -0.07 -2.80%

Inhibikase Therapeutics Inc (IKT)

Overview News Price History Financials Discussions Forecast Stock Split

Inhibikase Therapeutics Inc stock is traded at $2.50, with a volume of 245.96K. It is down -0.79% in the last 24 hours and up +2.46% over the past month. Inhibikase Therapeutics Inc a clinical-stage pharmaceutical company developing therapeutics to modify the course of cardiopulmonary diseases, namely, Pulmonary Arterial Hypertension (PAH), in which aberrant signaling through type III receptor tyrosine kinases, including platelet derived growth factor receptors and a stem cell factor receptor, known as c-Kit, has been implicated. Its product candidate is IKT-001, a prodrug of imatinib mesylate (imatinib), for PAH which is an orphan indication. The company has developed its own portfolio of protein kinase inhibitors to treat bacterial and viral infections, including viral infections in the brain. It has one reporting segment, which is the business of developing protein kinase inhibitor therapeutics.

Previous Close:

$2.52

Open:

$2.49

24h Volume:

245.96K

Relative Volume:

0.32

Market Cap:

$348.84M

Revenue:

$79,600

Net Income/Loss:

$-48.26M

P/E Ratio:

-5.0792

EPS:

-0.4922

Net Cash Flow:

$-28.24M

1W Performance:

+3.73%

1M Performance:

+2.46%

6M Performance:

+28.21%

1Y Performance:

+46.20%

1-Day Range:

$2.475

$2.55

1-Week Range:

$2.27

$2.61

52-Week Range:

$1.33

$2.61

Inhibikase Therapeutics Inc Stock (IKT) Company Profile

Name

Inhibikase Therapeutics Inc

Sector

Healthcare (1074)

Industry

Biotechnology (600)

Phone

(302) 295-3800

Address

1000 N. WEST STREET, SUITE 1200, WILMINGTON

Employee

Twitter

Next Earnings Date

2026-08-13

Latest SEC Filings

IKT's Discussions on Twitter

Compare IKT vs VRTX, REGN, ARGX, MRNA, RVMD

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
IKT Inhibikase Therapeutics Inc	2.50	327.91M	79,600	-48.26M	-28.24M	-0.4922
VRTX Vertex Pharmaceuticals Inc	546.12	136.93B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	827.72	85.11B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	1,033.15	64.95B	4.16B	1.29B	734.26M	19.58
MRNA Moderna Inc	145.55	53.23B	2.23B	-3.19B	-1.60B	-8.1462
RVMD Revolution Medicines Inc	210.02	45.38B	742.00K	-1.37B	-1.07B	-7.0731

Inhibikase Therapeutics Inc Stock (IKT) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Mar-04-26	Initiated	Ladenburg Thalmann	Buy
Jan-21-26	Initiated	BofA Securities	Buy
Dec-26-25	Initiated	H.C. Wainwright	Buy
Dec-11-25	Initiated	Cantor Fitzgerald	Overweight
Feb-12-25	Downgrade	H.C. Wainwright	Buy → Neutral

Inhibikase Therapeutics Inc Stock (IKT) Latest News

Sep 03, 2026

Inhibikase Therapeutics, Inc. (NASDAQ:IKT) Receives Average Recommendation of "Buy" from Brokerages - MarketBeat

Sep 03, 2026

Sep 01, 2026

Inhibikase Therapeutics (NASDAQ:IKT) Stock Price Down 4.1%What's Next? - MarketBeat

Sep 01, 2026

Aug 26, 2026

Inhibikase Therapeutics Appoints Deloitte & Touche LLP After Dismissing CohnReznick LLP as Auditor - Kalkine Media

Aug 26, 2026

Aug 21, 2026

Inhibikase (IKT) Chart: Adds 1.70% to Close at $2.39 in Latest Trading; Trading Range: the Supplied Trading Band Runs From $2.27 to $2.51 for the Current SessionFibonacci Extension - siam.in

Aug 21, 2026

Aug 19, 2026

Inhibikase (IKT) Q1 2026 Results: EPS Prints Above Forecast; Post-Earnings: Shares Finish 0.42% Higher at the CloseFree Cash Flow Trends - vinanet.vn

Aug 19, 2026

Aug 18, 2026

Inhibikase Therapeutics Number of Employees 2026 | Employee Count & Headcount Data - Revelio Labs

Aug 18, 2026

Inhibikase Loss Widens as Phase 3 PAH Trial Expands - MyChesCo

Aug 18, 2026

Aug 17, 2026

Inhibikase Therapeutics (IKT) Slips 1.5% as Shares Test Support at $2.25Shakeout Pattern - vinanet.vn

Aug 17, 2026

Aug 16, 2026

Inhibikase Therapeutics (IKT) Holds Steady at $2.41 as Shares Consolidate Between $2.29 Support and $2.53 ResistanceReversal Setup Alerts - vinanet.vn

Aug 16, 2026

Aug 14, 2026

Perceptive group (IKT) discloses 6.9% Inhibikase stake through 10.3M warrant shares - Stock Titan

Aug 14, 2026

Nantahala reports 4.30% Inhibikase (IKT) stake across 5.81M shares - Stock Titan

Aug 14, 2026

symbol__ Stock Quote Price and Forecast - CNN

Aug 14, 2026

Aug 13, 2026

Sands Capital group (NASDAQ: IKT) discloses 9.3% Inhibikase stake plus large warrants - Stock Titan

Aug 13, 2026

Oppenheimer Maintains Inhibikase Therapeutics(IKT.US) With Buy Rating, Maintains Target Price $5 - Moomoo

Aug 13, 2026

Inhibikase Therapeutics Faces Rising BIOSECURE, China Supply Chain and Trial Risks That Could Disrupt Growth - TipRanks

Aug 13, 2026

Aug 12, 2026

Inhibikase Therapeutics, Inc. reports results for the quarter ended June 30Earnings Summary - TradingView

Aug 12, 2026

Aug 11, 2026

Is Inhibikase Therapeutics Inc (IKT) Positioned for Growth After Reporting $0.11 Loss? GF Score: 36/100 - GuruFocus

Aug 11, 2026

LifeSci Capital Maintains Inhibikase Therapeutics(IKT.US) With Buy Rating, Maintains Target Price $5 - Moomoo

Aug 11, 2026

Inhibikase grants $2.03 stock options to seven new hires - scanx.trade

Aug 11, 2026

Inhibikase Q2 EPS of $(0.11) meets analyst consensus estimates - scanx.trade

Aug 11, 2026

Inhibikase Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com

Aug 11, 2026

Inhibikase Therapeutics Announces Second Quarter 2026 Financial Results and Highlights Recent Activity - Yahoo Finance

Aug 11, 2026

Aug 10, 2026

Inhibikase Therapeutics, Inc. expected to post a loss of 11 cents a shareEarnings Preview - TradingView

Aug 10, 2026

Aug 09, 2026

Inhibikase Therapeutics, Inc. (NASDAQ:IKT) Given Consensus Recommendation of "Buy" by Brokerages - MarketBeat

Aug 09, 2026

Aug 02, 2026

Perceptive Advisors LLC Sells 3,106,568 Shares of Inhibikase Therapeutics, Inc. $IKT - MarketBeat

Aug 02, 2026

Aug 01, 2026

Inhibikase Therapeutics (IKT) Declines 4.4% as Stock Pressures Key $2.07 Support ZoneBreadth Thrust - dars.gov.et

Aug 01, 2026

Jul 31, 2026

Inhibikase Therapeutics, Inc. Revenue Breakdown – NASDAQ:IKT - TradingView

Jul 31, 2026

Inhibikase Wins FDA Orphan Status for PAH Drug Candidate - MyChesCo

Jul 31, 2026

18,030,000-share swap for warrant by Inhibikase Therapeutics, Inc. (IKT) - Stock Titan

Jul 31, 2026

H.C. Wainwright reiterates Inhibikase stock rating on FDA orphan drug status - Investing.com Canada

Jul 31, 2026

RA Capital group (NASDAQ: IKT) discloses 9.99% capped stake via stock and warrants - Stock Titan

Jul 31, 2026

Jul 29, 2026

Inhibikase Therapeutics Q1 2026 Earnings: Narrower Loss Beats Estimates as Pipeline Progress Continues - dars.gov.et

Jul 29, 2026

Jul 28, 2026

Inhibikase Therapeutics (IKT) Slips 1% as Shares Test Key Support at $2.21RVOL Breakout - dars.gov.et

Jul 28, 2026

Jul 27, 2026